Program
bilastine
Also written as “Bilastine”, “Bilastine oral dispersible tablets” and “Bilaxten oral dispersible tablets”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Conjunctivitis, Allergic · Urticaria · Rhinitis, Allergic · Asthma, led by 4 companies.
Drug pageBilastine: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Faes Farmaits history only | 140 open or running | phase 3since Jan 9, 2007 | Jan 8, 2007 | none ahead |
| Menarini Group | 30 open or running | phase 4since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jun 20, 2025 | Jun 20, 2025 | none ahead |
| Yuhanits history only | 10 open or running | phase 3since Jul 20, 2011 | Jul 20, 2011 | none ahead |
Also a collaborator on its studies: ORA, Dynamic Science S.L., Allied Research International and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Menarini Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2015First study: phase 4 study in Rhinitis, AllergicFirst studyNCT02576041 · 19 enrolled · Italy
- Apr 28, 2016Phase 4 study in AsthmaNCT02761252 · 454 enrolled · Croatia, Czechia, Germany and more
- Aug 3, 2018Phase 1 study in PharmacokineticsNCT03633760 · 24 enrolled · China
TargetBeta
“Histamine H1 receptor inverse agonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| fexofenadinerule | Sanofi | phase 4 | 38 |
| Diphenhydraminerule | Johnson & Johnson | phase 4 | 16 |
Studies
All 3 Menarini Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03633760Pharmacokinetics · China | 1 | UNKNOWN | Apr 30, 2019 | 24 |
| NCT02761252Asthma · Croatia, Czechia, Germany and more | 4 | Completed | Nov 24, 2016 | 454 |
| NCT02576041Rhinitis, Allergic · Italy | 4 | Completed | Dec 2015 | 19 |
How it is read
Names in the registry
- “Bilastine”, 13 entries
- “bilastine”, 2 entries
- “Bilastine oral dispersible tablets”, 1 entry
- “Bilaxten oral dispersible tablets”, 1 entry
- “Bilastine 0.2%”, 1 entry
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 6 studies
- Conjunctivitis, Allergic, 3 studies
- Urticaria, 2 studies
- Rhinitis, Allergic, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.